At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 224 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Phase II Randomized, Placebo-Controlled Clinical Trial for the Prevention and Progression of SARS-CoV-2 Infection of Subjects and Patients Using a Supplement Treatment With Carnipure Tartrate ( LCLT)
In Brief
A Phase 2 clinical trial evaluating LCLT : 68% elemental L-carnitine and 32 % Tartric acid and Placebo for COVID-19 Virus Infection. Completed, enrolled 224 participants across 1 site.
Detailed Summary
The purpose of the study is to assess safety and efficacy of Carnipure tartrate (L-Carnitine and L-tartaric acid - LCLT) supplementation for SARS-Cov-2 infection
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19 Virus Infection
CountriesBrazil
CollaboratorsHospital Espanhol
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartMar 2021
Primary CompletionSep 2021
Study CompletionFeb 2022
First PostedJul 2022
TodayJul 2026
First PostedJul 7, 2022
Enrollment StartMar 1, 2021
Primary CompletionSep 1, 2021
Study CompletionFeb 3, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.0 years ago
Interventions
LCLT : 68% elemental L-carnitine and 32 % Tartric aciddietary
3 g orally capsules
Placebodrug
orally capsules